|
Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies. |
|
|
Honoraria - Bayer; Merck Serono; Roche; SERVIER |
Consulting or Advisory Role - Bayer; Merck Serono; SERVIER |
Travel, Accommodations, Expenses - Bayer; Merck Serono; Sanofi |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Helsinn Healthcare; Lilly; MSD Oncology; Novartis; Pfizer; Roche (Inst) |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Ipsen; Léo Pharma; Roche; Roche; SERVIER |
Consulting or Advisory Role - Bristol-Myers Squibb; HalioDx; MSD Oncology |
Research Funding - Bayer (Inst) |
Travel, Accommodations, Expenses - Bayer; Hospira; Ipsen; Roche; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Merck Serono |
Travel, Accommodations, Expenses - Merck Serono; Roche |
|
|
Honoraria - Bayer; Merck Serono; Roche/Genentech; SERVIER; TERUMO |
Consulting or Advisory Role - Bayer; Biocompatibles; Helsinn Therapeutics; Merck Serono; Roche; Servier; Terumo |
Research Funding - Roche/Genentech; Sanofi |
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche/Genentech |